Benzinga | Aug 16, 2021 08:36AM EDT

DMC Recommends Biophytis Continue Sarconeos COVID-19 Study

* The Data Monitoring Committee (DMC) has recommended Biophytis SA (NASDAQ:BPTS) to continue patient recruitment into part 2 of Phase 2-3 COVA Study in COVID-19, with the protocol unmodified after reviewing of safety data.

* The COVA clinical program is assessing Sarconeos (BIO101) in patients aged 45 and older hospitalized with severe respiratory manifestations of COVID-19.

* The independent DMC meeting was dedicated to analyzing safety data from the first 155 randomized patients.

* The DMC will review the efficacy data of the 155 patients in Q3 2021 as part of the second Interim analysis to recommend futility and final sample size.

* The Company is progressing to complete the recruitment of the 310 patients and report top-line results in Q4 of 2021.

* Price Action: BPTS shares closed 1.27% higher at $8.54 on Friday.

* Related content: Benzinga's Full FDA Calendar.